Primary endpoint |
Complete cessation of migraine during the follow up. |
Secondary efficacy endpoints |
Mean reduction of monthly migraine attacks. Mean reduction of monthly migraine days. Responder rate. |
Secondary safety endpoints |
All-cause mortality. Peripheral embolism. New-onset arrhythmia warranting intervention. New-onset myocardial infarction. Other complications related to PFO closure procedure, device and antiplatelet drugs. Other side effects associated with the drugs used in the study. |